Research ArticleGENE THERAPY

Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model

See allHide authors and affiliations

Science Advances  13 Mar 2015:
Vol. 1, no. 2, e1500078
DOI: 10.1126/sciadv.1500078
  • Fig. 1 AAV9-GFP and AAV9-IGHMBP2 efficiently transduce tissues in nmd mice.

    (A) In vivo experimental design: newborn (P1) nmd mice were injected with AAV9-GFP, AAV9-IGHMBP2, or AAV9-null for a total dose of 5 × 1011 vg. (B) Injection of AAV9-GFP in wild-type (WT) animals resulted in GFP expression (green) within the spinal cord 2 weeks after injection. (C) Colocalization of GFP (green) with SMI32 (red) demonstrated that motor neurons were efficiently transduced. (D) Western blots of spinal cords revealed increased levels of IGHMBP2 in AAV9-IGHMBP2-nmd versus AAV9-null-nmd animals. (E) Quantification of IGHMBP2 levels in the spinal cord. Values are means ± SEM of IGHMBP2:β-actin expression levels (n = 5), *P < 0.01. Scale bars, 500 μm (B) and 50 μm (C).

  • Fig. 2 AAV9-IGHMBP2 increases motor neuron and axon number.

    (A) Representative motor neuron pools in the lumbar segment of the spinal cords of AAV9-IGHMBP2-nmd, AAV9-null-nmd, and WT mice at 4 weeks of age. (B) Quantification of motor neurons in the lumbar spinal cords of treated mice and WT mice (mean ± SD) at 4 weeks of age (n = 6 per group per time point). (C) Quantification of myelinated axons in the L4 anterior roots in WT, AAV9-IGHMBP2-nmd, and AAV9-null nmd mice (mean ± SD) at 4 weeks of age (n = 6 per group per time point). Motor neuron and myelinated axon counts significantly increased in the AAV9-IGHMBP2 treatment group compared to the AAV9-null group (*P < 0.0001). (D) Representative images of the L4 anterior roots of AAV9-IGHMBP2-nmd, AAV9-null-nmd, and WT mice at 4 weeks of age. Scale bar, 50 μm (A and D).

  • Fig. 3 AAV9-IGHMBP2 improves NMJs and the size of myofibers in skeletal muscles.

    (A and B) NMJs in the quadriceps, gastrocnemius, and diaphragm muscles improved after gene therapy. (A) Representative images of NMJs from the quadriceps of WT, AAV9-IGHMBP2-nmd, and AAV9-null-nmd mice. Neurofilament Ab, green; α-bungarotoxin, red. The asterisk highlights an unoccupied NMJ. Scale bar, 20 μm. (B) Percentage of denervated NMJs in gastrocnemius, quadriceps, and diaphragm muscles (mean ± SEM; *P < 0.001). (C and D) AAV9-IGHMBP2 treatment influenced fiber caliber in nmd quadriceps, gastrocnemius, and diaphragm muscles. (C) Representative images of quadriceps and diaphragm muscle fibers at 4 weeks stained with hematoxylin and eosin (H&E). Increased numbers of perimysial and central cell nuclei were observed in untreated nmd mice; these numbers declined after AAV9-IGHMBP2 treatment. Scale bar, 100 μm. (D) Significant reductions in fiber caliber were evident in AAV9-null-nmd mice versus control mice; AAV9-IGHMBP2 treatment ameliorated this effect. Values are means ± SEM.

  • Fig. 4 AAV9-IGHMBP2 treatment improves neuromuscular function and survival in nmd mice.

    (A) Representative images of AAV9-IGHMBP2-nmd mice showing their capacity to extend their hindlimbs in comparison to AAV9-null-nmd mice. (B) Rotarod test data. The performance of AAV9-IGHMBP2-nmd mice was significantly improved versus AAV9-null-nmd mice, which were never able to complete the test (P < 0.0001). Error bars denote SEM. (C) The mean body weight of AAV9-IGHMBP2-nmd mice significantly increased relative to AAV9-null-nmd mice (P< 0.01). Error bars show SEM. (D) Kaplan-Meier survival curves of AAV9-IGHMBP2-nmd mice and AAV9-null-nmd mice (P < 0.0001). For all graphs: AAV9-IGHMBP2-nmd mice, n = 17; AAV9-null-nmd mice, n = 24.

  • Fig. 5 AAV9-IGHMBP2 treatment protects human iPSC-derived spinal motor neurons from SMARD1-induced degeneration.

    (A) Schematic of the experimental strategy used to differentiate motor neurons from iPSCs. (B) Compared to WT (left), significantly fewer SMARD1 motor neurons were observed after long-term culture (right). Genetic correction with IGHMBP2 increased the number of SMARD1 motor neurons (TR-SMARD1, middle panel). SMI32, green; ChAT, red; DAPI, blue. Scale bar, 75 μm. (C) Genetic correction (green bar) protected motor neurons in long-term culture, increasing their survival versus SMARD1 cells (yellow bar) (8 weeks, *P < 0.001). (D) At 8 weeks, SMARD1 motor neurons (yellow) presented shorter axons than did WT cells (black). TR-SMARD1 (green) had longer axons than did SMARD1 motor neurons (P < 0.001). (E) IGHMBP2 staining (green) of WT motor neurons (left), SMARD1 motor neurons (right), and TR-SMARD1 (middle). Nuclei were counterstained with DAPI (blue). Scale bar, 70 μm. (F) Western blot of genetically corrected SMARD1 iPSCs (TR-SMARD1) indicated significantly increased expression of IGHMBP2 with respect toSMARD1 cells (SMARD1). (G) Quantification of IGHMBP2 levels in transfected SMARD1 iPSCs (TR-SMARD1) versus untransfected SMARD1 cells (SMARD1). Values are means ± SEM (*P < 0.01).

Supplementary Materials

  • Supplementary material for this article is available at

    Fig. S1. Validation of IGHMBP2 constructs in vitro and in vivo.

    Fig. S2. AAV9-IGHMBP2 administration ameliorates SMARD1 cardiomyopathy.

    Movie S1. Gross appearance of an AAV9-IGHMBP2–treated nmd mouse.

  • Supplementary Materials

    This PDF file includes:

    • Fig. S1. Validation of IGHMBP2 constructs in vitro and in vivo.
    • Fig. S2. AAV9-IGHMBP2 administration ameliorates SMARD1 cardiomyopathy.
    • Legend for movie S1

    Download PDF

    Other Supplementary Material for this manuscript includes the following:

    • Movie S1 (.mp4 format). Gross appearance of an AAV9-IGHMBP2–treated nmd mouse.

    Files in this Data Supplement:

Navigate This Article